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Abstract
IMPORTANCE Bone resorption inhibitors (BRIs) are recommended by international guidelines to
prevent skeletal-related events (SREs) among patients with metastatic castration-resistant prostate
cancer (mCRPC) and bone metastases. Abiraterone acetate with prednisone is currently the most
common first-line therapy for the treatment of patients with mCRPC; however, the clinical impact of
the addition of BRIs to abiraterone acetate with prednisone in this disease setting is unknown.
OBJECTIVE To evaluate the association of the use of concomitant BRIs with overall survival (OS) and
time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate
with prednisone as first-line therapy.
DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study collected data from 745
consecutive patients who began receiving abiraterone acetate with prednisone as first-line therapy
for mCRPC with bone metastases between January 1, 2013, and December 31, 2016. Data were
collected from 8 hospitals in Canada, Europe, and the US from June 15 to September 15, 2019.
EXPOSURES Patients were classified by receipt vs nonreceipt of concomitant BRIs and subclassified
by volume of disease (high volume or low volume, using definitions from the Chemohormonal
Therapy Vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
[CHAARTED] E3805 study) at the initiation of abiraterone acetate with prednisone therapy.
MAIN OUTCOMES AND MEASURES The primary end point was OS. The secondary end point was
time to first SRE. The Kaplan-Meier method and Cox proportional hazards models were used.
RESULTS Of the 745 men (median age, 77.6 years [interquartile range, 68.1-83.6 years]; 699 White
individuals [93.8%]) included in the analysis, 529 men (71.0%) received abiraterone acetate with
prednisone alone (abiraterone acetate cohort), and 216 men (29.0%) received abiraterone acetate
with prednisone plus BRIs (BRI cohort). A total of 420 men (56.4%) had high-volume disease, and
276 men (37.0%) had low-volume disease. The median follow-up was 23.5 months (95% CI, 19.8-
24.9 months). Patients in the BRI cohort experienced significantly longer OS compared with those in
the abiraterone acetate cohort (31.8 vs 23.0 months; hazard ratio [HR], 0.65; 95% CI, 0.54-0.79;
P < .001). The OS benefit in the BRI cohort was greater for patients with high-volume vs low-volume
disease (33.6 vs 19.7 months; HR, 0.51; 95% CI, 0.38-0.68; P < .001). The BRI cohort also had a
significantly shorter time to first SRE compared with the abiraterone acetate cohort (32.4 vs 42.7
months; HR, 1.27; 95% CI, 1.00-1.60; P = .04), and the risk of a first SRE was more than double in the
subgroup with low-volume disease (HR, 2.29; 95% CI, 1.57-3.35; P < .001). In the multivariable
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Abstract (continued)
analysis, concomitant BRIs use was independently associated with longer OS (HR, 0.64; 95% CI,
0.52-0.79; P < .001).
CONCLUSIONS AND RELEVANCE In this study, the addition of BRIs to abiraterone acetate with
prednisone as first-line therapy for the treatment of patients with mCRPC and bone metastases was
associated with longer OS, particularly in patients with high-volume disease. These results suggest
that the use of BRIs in combination with abiraterone acetate with prednisone as first-line therapy for
the treatment of mCRPC with bone metastases could be beneficial.
JAMA Network Open. 2021;4(7):e2116536. doi:10.1001/jamanetworkopen.2021.16536
Introduction
Prostate cancer is associated with the death of more than 360 000 men per year worldwide.1
Metastatic castration-resistant prostate cancer (mCRPC) is the advanced state of disease during
which most deaths occur, and the median overall survival (OS) among patients with mCRPC is
approximately 30 months.2-4 Mortality risk increases with the spread of the disease to the bone,
which is a preferential site of metastasis for prostate cancer.5 In this respect, the number of bone
metastases, the presence of bone pain, and the occurrence of skeletal-related events (SREs) is
associated with shorter survival.6,7
Zoledronic acid, the most potent of the bisphosphonates, and denosumab, a monoclonal
antibody directed against the receptor activator of nuclear factor κB ligand (RANKL), are osteoclast-
mediated bone resorption inhibitors (BRIs) that are approved for the prevention of SREs in patients
with CRPC and bone metastases and are recommended by international guidelines for use in this
disease setting.8-12 However, neither of these agents alone was associated with a survival benefit
among men with CRPC and bone metastases in phase 3 randomized clinical trials.13 Nevertheless,
post hoc analyses of prospective studies suggested that the combination of BRIs with the androgen
biosynthesis inhibitor abiraterone acetate with prednisone or the bone-targeting radionuclide
radium-223 may provide a survival benefit compared with placebo.14,15 In this regard, receipt of
abiraterone acetate with prednisone vs placebo with prednisone was associated with increases in the
longevity of chemotherapy-naive patients with mCRPC in the pivotal phase 3 study, COU-AA-302
(Abiraterone Acetate Plus Prednisone Vs Placebo Plus Prednisone in Chemotherapy-Naïve Men With
Metastatic Castration-Resistant Prostate Cancer).3 In addition, abiraterone acetate with prednisone
was associated with significant reductions in pain, delays in pain progression, and, similar to
zoledronic acid and denosumab, prevention of SREs.16
Abiraterone acetate with prednisone is currently the most commonly administered first-line
therapy for patients with mCRPC.17 Because BRIs do not impact OS and because abiraterone acetate
with prednisone has been associated with the prevention of SREs, the addition of BRIs is often
omitted based on the rationale that BRIs would not add benefit to abiraterone acetate with
prednisone alone. Nonetheless, BRIs and abiraterone acetate with prednisone have different and
potentially complementary mechanisms of action; thus, it is possible that their concomitant use may
produce synergistic benefits.8,10,18 However, to date, the clinical outcomes of the addition of BRIs to
abiraterone acetate with prednisone compared with abiraterone acetate with prednisone alone as
first-line therapy for patients with mCRPC and bone metastases have not been investigated. Given
the potential for adverse events, including hypocalcemia, osteonecrosis of the jaw, and kidney
impairment, and the costs associated with BRI use, evaluating whether these agents add clinical
benefit to abiraterone acetate with prednisone is an important clinical question.8-10
In this study, we sought to assess the clinical impact associated with BRIs among men with
mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. We
also conducted a subgroup analysis to evaluate the clinical outcomes of the combination of
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abiraterone acetate with prednisone plus BRIs vs abiraterone acetate with prednisone alone among
patients with high-volume vs low-volume disease.19
Methods
This cohort study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline. Eight institutions in Canada, Europe, and the US
participated in the study, and institutional review board approval was granted in each center before
the study began. The study was given a waiver of informed consent because all data were
deidentified.
Study Cohorts
Clinical and electronic registries from the 8 participating hospitals were queried to identify a cohort
of consecutive patients with histologically confirmed CRPC (defined using Prostate Cancer Clinical
Trial Working Group 3 criteria20) and radiologically quantifiable bone metastases who began
receiving abiraterone acetate with prednisone as first-line therapy for mCRPC between January 1,
2013, and December 31, 2016. This specific time frame accounted for the European Medicines
Agency approval date of abiraterone acetate with prednisone for the treatment of chemotherapy-
naive mCRPC (2013) and the need for an adequate follow-up period. Data were collected from June
15 to September 15, 2019.
Patients who had received any therapy for mCRPC before initiation of abiraterone acetate with
prednisone and patients who had received abiraterone acetate with prednisone for the treatment
of metastatic hormone-sensitive prostate cancer were not included in the study. Patients who
experienced an SRE (defined as palliative local therapy to bone, pathological fractures, or spinal cord
compression) before beginning treatment with abiraterone acetate with prednisone were excluded,
as were those who initiated treatment with zoledronic acid or denosumab therapy more than 3
months after or before the initiation of abiraterone acetate with prednisone, with the exception of
osteoporosis treatment.
Demographic, pathologic, and clinical data, including type of metastatic disease presentation
(de novo or recurrent after previous local therapy), treatment for metastatic hormone-sensitive
prostate cancer (androgen deprivation therapy or androgen deprivation therapy plus docetaxel),
volume of disease (high or low), presence of any visceral metastases (including liver), presence of
liver metastases, Eastern Cooperative Oncology Group (ECOG) performance status, intensity of
cancer-associated pain (hereinafter referred to as pain), receipt of opioids at baseline, date of
initiation of palliative therapy for pain intensity, prostate-specific antigen measurements, and all
information related to BRI and abiraterone acetate with prednisone treatments were collected from
medical and electronic records. All patients were followed up until death, last follow-up visit, or
September 15, 2019 (data cutoff date), whichever occurred first.
Patients were categorized into 2 cohorts based on the receipt or nonreceipt of concomitant
BRIs; the abiraterone acetate cohort received abiraterone acetate with prednisone alone, and the BRI
cohort received abiraterone acetate with prednisone plus BRIs. Patients were also subclassified by
volume of disease, with high-volume disease defined as visceral metastases and/or at least 4 bone
metastases, including 1 or more metastases out of the axis and pelvis, and low-volume disease
defined as the absence of high-volume disease (based on definitions from the Chemohormonal
Therapy Vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
[CHAARTED] E3805 study19).
Outcomes
The primary end point of the study was OS, defined as the time from initiation of treatment with
abiraterone acetate with prednisone to the date of death from any cause, the date of the last
recorded clinical appointment, or the date of data cutoff, whichever came first. The secondary end
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point was time to first SRE, defined as the time from the initiation of abiraterone acetate with
prednisone to the date of the first radiologically documented SRE, the date of the last follow-up visit,
the date of data cutoff, or the date of death from any cause, whichever occurred first.
Statistical Analysis
Median values with interquartile ranges (IQRs) and frequencies with percentages were calculated for
the description of continuous and categorical variables, respectively. Medians and proportions were
compared using unpaired 2-sided t tests and χ2 tests, respectively. The Kaplan-Meier method was
used to calculate the distributions of the end points, including median time to event with 95% CIs,
and a log-rank test was applied to compare time to event distributions among the cohorts. The Cox
proportional hazards model was used to compare the estimates of the outcomes among the groups.
All variables were first tested using a univariable analysis. Variables with significant association
with the outcomes were used to build a multivariable model using the stepwise method, after
considering collinearity among variables using a correlation matrix with a cutoff value of 0.7. Variables
higher than this threshold were further tested using the variance inflation factor. In cases in which
the variance inflation factor was greater than 5, the collinearity was deemed excessive, and
modifications to the model were considered, including the removal of the variable. In our database,
less than 10% of patients had some missing data (at random); therefore, complete case analyses
were performed to remove patients with missing data for the variable of interest. To address the
potential bias associated with the exclusion of missing data, we compared characteristics of patients
included in the multivariable model for OS (without missing data) with those of the general
population (eTable 1 in the Supplement).
The assumption of proportionality was verified by plotting log-minus-log survival curves and by
cumulative martingale process plots. First-order interactions were assessed for each multivariable
model. Covariates included in the multivariable Cox models were clinicopathological factors known
to be associated with survival and time to first SRE, such as Gleason score, previous local therapy
(surgery or radiotherapy), de novo disease, receipt of treatment for metastatic hormone-sensitive
prostate cancer, baseline volume of disease, liver metastases, ECOG performance status, pain
intensity, receipt of opioids, and prostate-specific antigen value.7,21-23
All statistical tests were 2-sided with a significance threshold of P  .05. Statistical analyses




Of the 745 patients (median age, 77.6 years [IQR, 68.1-83.6 years]; 699 White individuals [93.8%])
eligible for this analysis, 529 patients (71.0%) received abiraterone acetate with prednisone alone,
and 216 patients (29.0%) received abiraterone acetate with prednisone plus concurrent BRIs
(eFigure in the Supplement). Demographic and pathologic characteristics were comparable between
the 2 cohorts (Table 1). A total of 420 men (56.4%) had high-volume disease, and 276 men (37.0%)
had low-volume disease. The median follow-up was 23.5 months (95% CI, 19.8-24.9 months). In the
BRI cohort, 132 patients (61.1%) received denosumab, and 84 patients (38.9%) received zoledronic
acid. The median time from the initiation of treatment with abiraterone acetate with prednisone to
the addition of BRIs was 15 days (IQR, 0-68 days), and the median duration of BRI use was
approximately 2 years (median, 741 days; IQR, 362-1182 days).
As expected, at baseline, the proportion of patients with low pain intensity (defined as a score
of <4 on the visual analog scale) was greater (389 patients [73.5%] vs 125 patients [57.9%]), and the
receipt of opioids was less common (65 patients [12.3%] vs 34 patients [15.5%]) in the abiraterone
acetate cohort vs the BRI cohort. High-volume disease was present in 336 patients (63.5%) in the
abiraterone acetate cohort vs 84 patients (38.9%) in the BRI cohort. A total of 287 patients (54.3%)
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cohort (n = 529)
BRI cohort
(n = 216)
Age at baseline, median (IQR), y 77.6 (68.1-83.6) 78.3 (70.5-85.4) 75.8 (66.9-81.2) .10
Race
White 699 (93.8) 497 (94.0) 202 (93.5)
.08Othera 19 (2.6) 10 (1.9) 9 (4.2)
Not available 27 (3.6) 22 (4.2) 5 (2.3)
Gleason score
≤6 62 (8.3) 42 (7.9) 20 (9.3)
.53
7 218 (29.3) 145 (27.4) 73 (33.8)
≥8 337 (45.2) 234 (44.2) 103 (47.7)
Not available 128 (17.2) 108 (20.4) 20 (9.3)
Previous local therapy
No 353 (47.4) 265 (50.1) 88 (40.7)
.03
Surgery 196 (26.3) 127 (24.0) 69 (31.9)
Radiotherapy 181 (24.3) 125 (23.6) 56 (25.9)
Not available 15 (2.0) 12 (2.3) 3 (1.4)
De novo
No 483 (64.8) 340 (64.3) 143 (66.2)
.64
Yes 262 (35.2) 189 (35.7) 73 (33.8)
Treatment for mHSPC
ADT 617 (82.8) 475 (89.8) 142 (65.7)
<.001ADT plus docetaxel 81 (10.9) 41 (7.8) 40 (18.5)
Not available 47 (6.3) 13 (2.5) 34 (15.7)
Volume of disease at baselineb
Low 276 (37.0) 179 (33.8) 97 (44.9)
<.001High 420 (56.4) 336 (63.5) 84 (38.9)
Not available 49 (6.6) 14 (2.6) 35 (16.2)
Visceral metastases at baseline
No 680 (91.3) 477 (90.2) 203 (94.0)
.09
Yes 65 (8.7) 52 (9.8) 13 (6.0)
Liver metastases at baseline
No 709 (95.2) 506 (95.7) 203 (94.0)
.33
Yes 36 (4.8) 23 (4.3) 13 (6.0)
ECOG performance status at baseline
0 324 (43.5) 224 (42.3) 100 (46.3)
.01≥1 369 (49.5) 287 (54.3) 82 (38.0)
Not available 52 (7.0) 18 (3.4) 34 (15.7)
Pain intensity at baseline, VAS
0-3 514 (69.0) 389 (73.5) 125 (57.9)
.03
4-5 112 (15.0) 71 (13.4) 41 (19.0)
>5 70 (9.4) 53 (10.0) 17 (7.9)
Not available 49 (6.6) 16 (3.0) 33 (15.3)
Receiving opioids at baseline
No 598 (80.3) 449 (84.9) 149 (69.0)
.05Yes 99 (13.3) 65 (12.3) 34 (15.7)
Not available 48 (6.4) 15 (2.8) 33 (15.3)
PSA at baseline, median (IQR), ng/mL 32 (10.0-98.5) 37.5 (12.2-126.2) 19.3 (6.4-57.0) .18
Receiving a BRI
No 529 (71.0) 529 (100) 0
NAZoledronic acid 84 (11.3) 0 84 (38.9)
Denosumab 132 (17.7) 0 132 (61.1)
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in the abiraterone acetate cohort vs 82 patients (38.0%) in the BRI cohort had an ECOG performance
status of 1 or higher. The number of patients receiving fewer than 2 therapies for mCRPC after receipt
of abiraterone acetate with prednisone was 417 (78.8%) in the abiraterone acetate cohort vs 94
(43.5%) in the BRI cohort. The rates of visceral metastases and liver metastases were relatively low
and comparable between those who received abiraterone acetate with prednisone (52 patients
[9.8%] and 23 patients [4.3%], respectively) and those who received abiraterone acetate with
prednisone plus BRIs (13 patients [6.0%] and 13 patients [6.0%], respectively).
Outcomes Associated With Concomitant BRI vs No BRI
The median OS among the 216 patients in the BRI cohort was 31.8 months (95% CI, 28.2-36.4
months) compared with 23.0 months (95% CI, 21.0-25.7 months) among those in the abiraterone
acetate cohort. The risk of death in the BRI cohort decreased by 35% (hazard ratio [HR], 0.65; 95%
CI, 0.54-0.79; P < .001) (Table 2). The Kaplan-Meier estimates illustrating the survival benefit
associated with the addition of BRIs to abiraterone acetate with prednisone therapy are shown in
Figure 1A. In contrast, albeit with less statistical significance, the BRI cohort experienced a decrease
in the median time to first SRE compared with the abiraterone acetate cohort (32.4 vs 42.7 months,
respectively; HR, 1.27; 95% CI, 1.00-1.60; P = .04). The negative association of the receipt of
concomitant BRIs with time to first SRE is shown in the Kaplan-Meier curves in Figure 1B.
In the multivariable analysis of OS, the addition of BRIs was independently associated with
improvement in OS (HR, 0.64; 95% CI, 0.52-0.79; P < .001), which was consistent with the outcomes
of the univariable model (HR, 0.65; 95% CI, 0.54-0.79; P < .001) (eTable 2 in the Supplement). The
type of BRI (denosumab vs zoledronic acid) received was not associated with OS (HR, 0.93; 95% CI,
0.66-1.30; P = .79). Independent associations with increased OS were also found for low-volume vs







cohort (n = 529)
BRI cohort
(n = 216)
Time from start of abiraterone acetate
with prednisone to start of BRI,
median (IQR), d
15 (0-68) NA 15 (0-68) NA
Duration of BRI receipt, median (IQR), d 741 (362-1182) NA 741 (362-1182) NA
No. of abiraterone acetate with
prednisone cycles, median (IQR)
9 (4-20) 10 (4-21) 7 (4-14) .01
Receiving pain palliation
No 198 (26.6) 127 (24.0) 71 (32.9)
.002Yes 497 (66.7) 386 (73.0) 111 (51.4)
Not available 50 (6.7) 16 (3.0) 34 (15.7)
No. of treatments received after
abiraterone acetate with prednisone
Median (IQR) 1 (0-2) 0 (0-1) 2 (1-3)
<.001
0-1 511 (68.6) 417 (78.8) 94 (43.5)
>1 225 (30.2) 112 (21.2) 113 (52.3)
Not available 9 (1.2) 0 9 (4.2)
Follow-up in overall population,
median (95% CI), mo
23.5 (19.8-24.9) 21.6 (17.2-25.3) 28.6 (22.5-34.3) .36
Abbreviations: ADT, androgen deprivation therapy;
BRI, bone resorption inhibitor; ECOG, Eastern
Cooperative Oncology Group; IQR, interquartile range;
mHSPC, metastatic hormone-sensitive prostate
cancer; NA, not available/not applicable; PSA,
prostate-specific antigen; VAS, visual analog scale.
a Races included in this category were not specifically
identified.
b High-volume disease was defined as visceral
metastases and/or at least 4 bone metastases,
including 1 or more metastases out of the axis and
pelvis. Low-volume disease was defined as the
absence of high-volume disease.
Table 2. Clinical Outcomes Among Overall Population by Receipt of Bone Resorption Inhibitors
Outcome
Abiraterone acetate
cohort (n = 529)
BRI cohort
(n = 216) HR (95% CI) P value
Deaths, No. 369 147 NA NA
OS, median (95% CI), mo 23.0 (21.0-25.7) 31.8 (28.2-36.4) 0.65 (0.54-0.79) <.001
SREs, No. 188 116 NA NA
Time to first SRE,
median (95% CI), mo
42.7 (33.2-52.2) 32.4 (24.1-37.3) 1.27 (1.0-1.60) .04
Abbreviations: BRI, bone resorption inhibitor; HR,
hazard ratio; NA, not applicable; OS, overall survival;
SRE, skeletal-related event.
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high-volume disease (HR, 0.66; 95% CI, 0.54-0.80; P < .001), previous local therapy vs no previous
local therapy (surgery vs no surgery: HR, 0.51; 95% CI, 0.39-0.68; P < .001; radiotherapy vs no
radiotherapy: HR, 0.71; 95% CI, 0.55-0.93; P = .03), liver metastases vs no liver metastases (HR,
2.04; 95% CI, 1.37-3.05; P = .006), ECOG performance status of 0 vs 1 or higher (HR, 1.46; 95% CI,
1.20-1.78; P = .003), baseline pain of 3 or lower vs 5 or higher on the visual analog scale (HR, 1.88;
95% CI, 1.39-2.54; P < .001), and baseline prostate-specific antigen level (HR, 1.03; 95% CI, 1.01-1.05;
P = .006). In the multivariable analysis of time to first SRE, compared with the results of the
univariable model, no association was found between the receipt of concomitant BRIs vs no BRIs and
delayed time to first SRE (eTable 3 in the Supplement). However, low-volume vs high-volume disease
and baseline pain of 3 or lower vs 4 to 5 or higher than 5 on the visual analog scale revealed
independent associations with improved time to first SRE. The survival advantage of concomitant
BRI in the overall population remained significant when stratified by the covariates (eTable 4 in the
Supplement) or centers (eTable 5 in the Supplement), even if a certain variability in covariate rates
and overall survival data was observed across centers (eTable 6 in the Supplement).
Subgroup Analysis by Disease Volume
The interaction tests of the abiraterone acetate and BRI cohorts by volume of disease (low vs high)
revealed a differential effect in the subgroups for both OS and time to first SRE. This result suggests
that the volume of disease modified the association of BRIs with the outcomes. In the subset of
patients with high-volume disease, the median OS favored patients receiving concurrent BRIs
(Figure 2A) who experienced a survival advantage (33.6 months; 95% CI, 24.8-46.3 months)
compared with those not receiving concurrent BRIs (19.7 months; 95% CI, 17.3-21.8 months; P < .001)
(Table 3). This OS benefit was greater than that observed in the overall population, with the risk of
death among men who received treatment with abiraterone acetate with prednisone plus BRIs
approximately halved compared with those receiving abiraterone acetate with prednisone alone
(HR, 0.51; 95% CI, 0.38-0.68; P < .001).
In contrast, there was no difference in median OS among those with low-volume disease,
regardless of whether they received concurrent BRIs (31.8 months [95% CI, 28.2-37.1 months] in the
BRI cohort vs 33.0 months [95% CI, 29.2-41.4 months] in the abiraterone acetate cohort; P = .62)
(Figure 2B). The detrimental consequences of concurrent BRI on the median time to first SRE
observed in the whole population was most substantial in the subgroup with low-volume disease
(Figure 2D). Patients with low-volume disease in the BRI cohort had a greater than 2-fold risk of
























































































































An SRE was defined as palliative surgery or radiotherapy to bone, pathological fractures, or spinal cord compression. AA indicates abiraterone acetate plus prednisone; BRI, bone
resorption inhibitor.
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experiencing an SRE compared with those in the abiraterone acetate cohort (HR, 2.29; 95% CI, 1.57-
3.35; P < .001). In contrast, patients with high-volume disease in the BRI cohort experienced a delay
in the median time to first SRE compared with those with high-volume disease in the abiraterone
Figure 2. Overall Survival and Time to First Skeletal-Related Event (SRE) in Subsets of Patients With High-Volume (HV) and Low-Volume (LV) Disease by Receipt
























































































































































































































An SRE was defined as palliative surgery or radiotherapy to bone, pathological fractures,
or spinal cord compression. High-volume disease was defined as visceral metastases
and/or at least 4 bone metastases, including 1 or more metastases out of the axis and
pelvis; LV disease, the absence of HV disease. A, Overall survival in patients with HV
disease. B, Overall survival in patients with LV disease. C, Time to first SRE in patients
with HV disease. D, Time to first SRE in patients with LV disease. AA indicates abiraterone
acetate plus prednisone; BRI, bone resorption inhibitor.
Table 3. Clinical Outcomes for Disease Volume Subgroups by Receipt of Bone Resorption Inhibitors
Outcome










(n = 97) HR (95% CI) P value
Deaths, No. 268 53 NA NA 114 63 NA NA
OS, median (95% CI), mo 19.7 (17.3-21.8) 33.6 (24.8-46.3) 0.51 (0.38-0.68) <.001 33.0 (29.2-41.4) 31.8 (28.2-37.1) 0.93 (0.68-1.26) .62
SREs, No. 135 34 NA NA 49 59 NA NA
Time to first SRE,
median (95% CI), mo
31.7 (25.2-38.1) 51.5 (31.6-NA) 0.70 (0.48-1.03) .07 NA (43.9-NA) 25.2 (20.9-40.0) 2.29 (1.57-3.35) <.001
Abbreviations: BRI, bone resorption inhibitor; HR, hazard ratio; NA, not available/not applicable; OS, overall survival; SRE, skeletal-related event.
a High-volume disease was defined as visceral metastases and/or at least 4 bone metastases, including 1 or more metastases out of the axis and pelvis.
b Low-volume disease was defined as the absence of high-volume disease.
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acetate cohort (HR, 0.70; 95% CI, 0.48-1.03; P = .07) (Figure 2C); however, this association was not
statistically significant.
Discussion
This large international cohort study is the first, to our knowledge, to evaluate the clinical impact
associated with the addition of BRIs (zoledronic acid or denosumab) to abiraterone acetate with
prednisone as first-line therapy for the treatment of patients with mCRPC and bone metastases. In
this analysis the addition of BRIs to first-line treatment with abiraterone acetate with prednisone was
associated with improvement in survival compared with abiraterone acetate with prednisone alone.
This survival association is consistent with the increasing body of evidence suggesting that treatment
with concurrent BRIs may provide an additive benefit to life-prolonging agents approved for the
treatment of mCRPC.14,15 In particular, a post hoc analysis of data from the COU-AA-302 study,14
which assessed the clinical outcomes of concurrent BRI use among men receiving abiraterone
acetate with prednisone or prednisone alone in a chemotherapy-naive setting, reported a survival
benefit associated with the combination of BRIs and abiraterone acetate with prednisone compared
with BRIs and prednisone alone (HR, 0.71; 95% CI, 0.50-1.00; P = .05). Because of the vintage of the
COU-AA-302 study, most patients (93%) received treatment with zoledronic acid rather than
denosumab.14
However, the phase 3b study conducted by the Radium-223 International Early Access Program
Investigators,15 which examined the use of radium-223 plus concomitant anticancer agents for men
with CRPC and bone metastases, suggested improved survival for those treated with concomitant
denosumab (median, not available [NA]; 95% CI, 15 months to NA) compared with those who
received radium-223 alone (median, 13 months; 95% CI, 12 months to NA).15 In the present analysis,
both BRI agents were used in a more balanced distribution, with 38.9% of patients receiving
zoledronic acid and 61.1% of patients receiving denosumab, and the type of BRI received was not
associated with OS in the univariable and multivariable analyses, suggesting that the class of BRI may
not be associated with OS findings. Therefore, a physician’s choice of type of BRI could be based on
patient preference, risk-benefit scenarios, and costs.
The present study is also the first, to our knowledge, to describe the outcomes associated with
the addition of BRIs to abiraterone acetate with prednisone as first-line therapy for men with CRPC
and bone metastases according to disease burden. Although international guidelines recommend
the use of BRIs for most men with CRPC and bone metastases with the aim of preventing SREs, the
volume of disease is currently not addressed.11,12 Nonetheless, an increasing body of evidence
suggests that the volume of disease may be associated with survival and the risk of SREs among
patients with prostate cancer.19,21,24 In the present analysis, men with high-volume disease and
worse prognosis who received concomitant BRIs had a clear survival benefit and a lower risk of
experiencing a first SRE compared with those who did not receive BRIs. In contrast, in the subset of
patients with low-volume disease, the receipt of concurrent BRIs was not associated with an OS
advantage and, for unclear reasons, the risk of experiencing a first SRE was almost 2-fold among
those in the BRI cohort compared with those in the abiraterone acetate cohort.
With respect to the time to first SRE outcomes, the data in the present study are consistent with
those of a contemporary single-institution analysis performed by McGregor et al,24 which reported
a lower risk of experiencing a first SRE among those receiving abiraterone acetate with prednisone or
the androgen receptor targeting agent enzalutamide plus BRIs when used as first-line therapy
compared with second-line therapy or no receipt of therapy (HR, 0.58; 95% CI, 0.36-0.95). This
reduction in SRE risk was limited to those with a disease burden of 4 bone metastases or more, which
approximates the E3805 definition of high-volume disease used in the present study.19 A post hoc
analysis of the randomized phase 3 ERA 223 (Addition of Radium-223 to Abiraterone Acetate and
Prednisone or Prednisolone in Patients With Castration-Resistant Prostate Cancer and Bone
Metastases) study,25 which compared the efficacy of the combination of abiraterone acetate with
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prednisone plus radium-223 vs abiraterone acetate with prednisone alone, found a lower rate of
bone fractures among patients receiving concomitant BRIs compared with those not receiving BRIs,
regardless of the treatment arm. Of note, approximately two-thirds of the ERA 223 study population
had at least 6 bone metastases.25 These collective findings support the hypothesis that the addition
of BRIs to abiraterone acetate with prednisone may have a protective benefit for the bones of
patients with high-volume disease, as observed in the present study.
In the multivariable analysis of the overall population, the volume of disease was found to be
independently associated with time to first SRE. Therefore, the negative outcome associated with
concurrent BRIs for time to first SRE seen in the overall population could be primarily associated with
the detrimental consequences occurring in the subset of patients with low-volume disease. However,
there is currently no clear biological rationale that may explain the deleterious consequences of the
addition of BRIs to abiraterone acetate with prednisone therapy for time to first SRE among men with
low-volume disease, and these findings should be interpreted with caution.
Limitations
This study has limitations. Skeletal-related events, albeit defined as any palliative radiotherapy or
surgery to bone metastases, pathological fractures, or spinal cord compression, were not adjudicated
or categorized by type when recorded. Therefore, we have no information about how the types of
SREs were distributed in each group, which could have offered insight into time to first SRE
outcomes. One possibility is that palliative radiotherapy was used earlier among men with
low-volume disease rather than proceeding with chemotherapy, whereas those with high-volume
disease were more likely to receive treatment with chemotherapy for symptomatic progression, and
these differences may have produced the observed shortening of time to first SRE in the subset of
patients with low-volume disease. Thus, further prospective studies and meta-analyses are
warranted to confirm these findings and acquire clearer insights on the potential differential benefits
of the use of concurrent BRIs plus abiraterone acetate with prednisone for the treatment of CRPC
and bone metastases among patients with high-volume vs low-volume disease and the biological
mechanisms underpinning this phenomenon.
This study is also limited by its retrospective design and lack of randomization. In addition, the
numerical and clinical imbalances among the cohorts may have biased the results. However, in an
additional survival analysis stratified by covariates, the receipt of concomitant BRIs was associated
with a survival advantage, regardless of the covariate used for stratification (eTable 4 in the
Supplement). Furthermore, the survival advantage conferred by BRI receipt remained significant in
the univariable and multivariable analyses of OS stratified by study center (eTable 5 in the
Supplement).
Another potential limitation to this study is the limited racial diversity of the population (93.8%
White). However, because the clinician’s choice was not directed by any specific protocol criteria,
this study yields useful real-world data that reflect clinical practice in the Western world (eTable 6 in
the Supplement). In this regard, it should be noted that most patients in our study (71.0%) did not
receive BRIs in combination with first-line abiraterone acetate with prednisone therapy and, notably,
most of these men (63.5%) had a high metastatic burden (Table 1). These data are similar to those
reported in the study by McGregor et al,24 in which 50% of patients did not receive BRIs in
combination with either first-line treatment with abiraterone acetate with prednisone or
enzalutamide, and most of those patients (58%) had 4 or more bone metastases. This finding may
reflect the common clinical behavior of withholding the use of BRIs for the treatment of CRPC with
bone metastases, which is contrary to international guideline recommendations11,12 and may suggest
physician skepticism regarding the utility of the addition of BRIs to a therapy such as abiraterone
acetate with prednisone, which has known SRE-delaying and survival-improving properties.
The present study found that the addition of BRIs to abiraterone acetate with prednisone was
associated with a robust survival advantage compared with abiraterone acetate with prednisone
alone, and this benefit was greater among patients with high-volume disease. However, given these
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limitations, the results cannot be generalized and warrant further confirmation by future prospective
clinical trials.
Conclusions
In this large multicenter retrospective cohort study, the addition of BRIs to abiraterone acetate with
prednisone as first-line therapy for patients with mCRPC and bone metastases was associated with
significantly longer survival compared with the use of abiraterone acetate with prednisone alone. A
greater survival benefit was observed among those with high-volume disease receiving concomitant
BRIs. Although these findings are not generalizable, they provide real-world data in favor of the
addition of BRIs to abiraterone acetate with prednisone as first-line therapy for patients with mCRPC
and bone metastases, and they support the international guideline recommendation of using BRIs
in this disease setting.
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